ctx-130,exa-cel
Vertex pharmaceuticals,CRISPR therapeutics AG
['thanks', 't-cell lymphoma', 'lymphoma']
one of the most exciting weekends for at 2022 meeting in vienna. remarkable data in sickle cell and tdt with ctx001, and new hope for patients with t-cell lymphomas with ctx130. many thanks to the team, our partners, investigators &amp; patients! #eha2022
CEO at CRISPR Therapeutics @CRISPRTx @McKinsey @UW @IITKGP Own opinions